WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522486
Description: DS-1558 is a potent and orally available GPR40 agonist.DS-1558 was found to have potent glucose lowering effects during an oral glucose tolerance test in ZDF rats. DS-1558 significantly and dose-dependently improved hyperglycemia and increased insulin secretion during the oral glucose tolerance test in Zucker fatty rats, the model of insulin resistance and glucose intolerance. DS-1558 not only increased the glucose-stimulated insulin secretion by GLP-1 but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats.
MedKoo Cat#: 522486
Chemical Formula: C21H21F3O4
Exact Mass: 394.13919
Molecular Weight: 394.39021
Elemental Analysis: C, 63.95; H, 5.37; F, 14.45; O, 16.23
Synonym: DS-1558; DS 1558; DS1558.
IUPAC/Chemical Name: (S)-3-ethoxy-3-(4-(((R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)propanoic acid
InChi Key: YHLQVQKZDZYMIP-MOPGFXCFSA-N
InChi Code: InChI=1S/C21H21F3O4/c1-2-27-19(12-20(25)26)13-6-8-14(9-7-13)28-18-11-10-15-16(18)4-3-5-17(15)21(22,23)24/h3-9,18-19H,2,10-12H2,1H3,(H,25,26)/t18-,19+/m1/s1
SMILES Code: FC(F)(F)C1=CC=CC2=C1CC[C@H]2OC(C=C3)=CC=C3[C@H](CC(O)=O)OCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 394.39021 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata
T, Watanabe N, Hirouchi M, Kimura T, Toda N. Optimization of
3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.
Bioorg Med Chem. 2015 Sep 1;23(17):5546-65. doi: 10.1016/j.bmc.2015.07.028. Epub
2015 Jul 23. PubMed PMID: 26234904.
2: Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata
T, Watanabe N, Hirouchi M, Yoneyama T, Ito S, Toda N. Discovery of DS-1558: A
Potent and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2015 Jan
13;6(3):266-70. doi: 10.1021/ml500391n. eCollection 2015 Mar 12. PubMed PMID:
25815144; PubMed Central PMCID: PMC4360146.
3: Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, Takano R, Inoue M,
Honda T, Kume S, Matsumoto K. Potentiation of insulin secretion and improvement
of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist
DS-1558 with glucagon-like peptide-1 receptor agonists. Eur J Pharmacol. 2014 Aug
15;737:194-201. doi: 10.1016/j.ejphar.2014.05.014. Epub 2014 May 22. PubMed PMID: